ClearPoint Neuro director sells $132,800 in stock

Published 13/06/2025, 00:32
ClearPoint Neuro director sells $132,800 in stock

Timothy T. Richards, a director at ClearPoint Neuro, Inc. (NASDAQ:CLPT), has sold 10,000 shares of the company’s common stock, according to a recent SEC filing. The transaction, which took place on June 10, 2025, was valued at approximately $132,800, with shares sold at a weighted average price of $13.28 each. The sale comes amid a remarkable year for CLPT, which has delivered a ~113% return over the past twelve months, according to InvestingPro data. The company, currently valued at $341 million, maintains a healthy balance sheet with liquid assets exceeding short-term obligations.

The sale was conducted to cover the tax liability related to the vesting of 21,903 shares under a restricted stock unit granted to Richards on May 16, 2024. Following this transaction, Richards retains ownership of 77,381 shares in the company. InvestingPro analysis indicates the stock is currently trading near its Fair Value, with 8 additional exclusive insights available to subscribers through the comprehensive Pro Research Report, which provides deep-dive analysis of CLPT among 1,400+ top US stocks.

In other recent news, ClearPoint Neuro Inc. reported its Q1 2025 revenue at $8.5 million, exceeding forecasts by 3.16% and marking an 11% increase from the previous year. This growth was largely attributed to a 70% surge in the Neurosurgery Navigation segment, despite a 63% decline in Capital Equipment and Software (ETR:SOWGn) revenue. The company is projecting annual revenue between $36 million and $41 million for 2025, with plans for 15-20 new site activations. ClearPoint Neuro is also pursuing GLP certification in the latter half of the year to support potential commercialization of new therapeutic products. The company recently secured funding from Overland Capital, providing financial flexibility with a new credit facility and equity investment. While operational cash burn increased by $2.3 million, ClearPoint Neuro remains focused on maintaining financial discipline. Analysts from Lake Street Capital Markets have noted the company’s progress and financial backing as positive developments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.